Diabetes Self-Management Blog

Do you have Type 1 diabetes and peripheral neuropathy? Then you may be interested in the Act1ve Trial, which is currently enrolling participants.

People with Type 1 diabetes lose the ability to produce both insulin and a related substance known as C-peptide. Current Type 1 treatment focus on replacing insulin, but not C-peptide. According to biopharmaceutical manufacturer Cebix, “Published clinical studies suggest that C-peptide is an active hormone in its own right and may be useful in treating complications of type 1 diabetes, particularly loss of sensation (neuropathy).” Cebix has developed a long-acting form of C-peptide (brand name Ersatta) that it will be evaluating in the Act1ve Trial.

Participants in the trial will receive either weekly injections of Ersatta (approximately 60% of enrollees) or a placebo (inactive treatment; approximately 40% of enrollees) for a year, and researchers will track the effects on a measure of nerve function known as nerve conduction velocity (NCV).

Participants will receive, at no cost, all study-related care, exams and medical testing from the study doctor, the investigational drug, and compensation for time and travel. To qualify for the trial, you must have had Type 1 diabetes for a minimum of five years, have been on a stable diabetes management regimen for at least three months, and be between 18 and 65 years of age. Trial sites in the United States are located in California, Georgia, Idaho, Massachusetts, Michigan, Montana, Nebraska, Nevada, New York, and Texas.

For more information about the trial, including complete eligibility requirements and details on how to enroll, visit the Cebix Web site or see the listing on ClinicalTrials.gov.

This blog entry was written by Web Editor Diane Fennell.

POST A COMMENT       
  

We are currently experiencing technical difficulties with our commenting system. Thank you for your patience as we work to resolve them.


What We're Reading
JDRF 2015 Children's Congress (11/17/14)
Diabetes Self-Management Readers' Poll: Support Groups (11/20/14)
Diabetes Self-Management Readers’ Poll: Daylight Saving Time (11/10/14)
World Diabetes Day (11/14/14)

Diabetic Complications
You Can Fight Chronic Pain With Food (11/10/14)
Mediterranean Diet May Benefit Kidneys (11/06/14)
Statins May Reduce Risk of Nerve Damage, Other Diabetes Complications (09/18/14)
New Approach for Neuropathy Pain? (08/18/14)

Diabetes Research
A Diabetes Cure in Mice (11/13/14)
Mediterranean Diet May Benefit Kidneys (11/06/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.